second quarter 2026
Filed Aug 6, 2026Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates
Record revenue, 66% year-over-year total product revenue growth, a 56% gross margin, and continued U.S. Amtagvi demand supported a review of FY26 revenue guidance.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Revenueother | $99.3 million | – | – |
| Total product revenueother | ~$99 million | 39% | 66% |
| Gross marginother | 56% | – | – |
| Research and Development (R&D) expensesother | decreased by ~6% | decreased by ~6% | – |
| Cash positionother | ~$304 million | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| U.S. Amtagvi revenueContinued U.S. Amtagvi demand, supported by a new marketing campaign and an expanded sales team, drove increased adoption across a growing ATC network and referrals toward earlier treatment. | ~$91 million | – | – |
| Global Proleukin revenueGlobal Proleukin revenue is expected to grow during the remainder of 2026. | ~$9 million | – | – |
FY26 outlook
- Revenue$350 million to $370 million, under review
- Gross marginImprovements in gross margin are expected to continue, excluding occasional one-time items.
- NoteAn update to FY26 total revenue guidance will be provided during the third quarter.
- NoteCurrent cash is expected to fund operations into 2H28.
- NoteAt least 110 ATCs are expected to be active by the end of 2026.
- NotePotential approval of the MAA in Switzerland is expected in 1H27.
- NoteProgram updates for IOV-LUN-202 are expected in 4Q26.
- NoteA supplemental Biologics License Application (sBLA) submission for IOV-LUN-202 is planned in 2027.
- NoteInitial data from investigator-sponsored trials in CSCC and MCC are expected in 1H27.
What drove it
- Total product revenue increased 66% from 2Q25 and 39% from 1Q26.
- Gross margin reflected higher Amtagvi sales volume, continued cost optimization, and maturing internal manufacturing efficiencies.
- R&D expenses decreased by ~6% compared to 1Q26, driven by continued operational efficiencies during the fourth straight quarter of improvements.
- Record Amtagvi demand was catalyzed by a new marketing campaign and an expanded sales team.
- The authorized treatment center network has grown to more than 95 U.S., Canadian, and Australian ATCs.
- Unaided physician awareness of Amtagvi has nearly tripled during the last year.
- Amtagvi turnaround time is 31 days or less using the centralized commercial manufacturing process approved by FDA for TIL therapy.
Concerns
- FY26 total revenue guidance of $350 million to $370 million is under review rather than updated in this release.
- Gross-margin improvement guidance excludes occasional one-time items.
- The U.K. MAA was resubmitted in early July and remains under expedited MHRA review for potential approval later in 2026.
- The European Medicines Agency MAA resubmission for Amtagvi in advanced melanoma is on track for 2027.
- Several pipeline programs remain in enrollment, early clinical development, or registrational studies.
What to watch
- The third-quarter update on FY26 total revenue guidance.
- Whether gross-margin improvements continue as expected, excluding occasional one-time items.
- Progress toward at least 110 active ATCs by the end of 2026 and growth in community ATCs.
- Potential U.K. Amtagvi approval later in 2026 and the expected Swiss MAA decision in 1H27.
- IOV-LUN-202 program updates expected in 4Q26 and the planned 2027 sBLA submission.
- SARATOGA results scheduled for an oral presentation at ESMO in Madrid, Spain, from October 23–27, 2026.
- Initial investigator-sponsored trial data in CSCC and MCC expected in 1H27.
Balance sheet and cash flow
- As of June 30, 2026, Iovance’s cash position was ~$304 million.
- Cash, cash equivalents, short-term investments, and restricted cash as of June 30, 2026.
- Current cash is expected to fund operations into 2H28.
Analysis
Iovance reported record second-quarter revenue of $99.3 million. Total product revenue was reported at approximately $99 million, up 66% from approximately $60 million in 2Q25 and 39% from approximately $71 million in 1Q26. U.S. Amtagvi revenue was approximately $91 million, while Global Proleukin revenue was approximately $9 million. The release attributes the result to continued U.S. Amtagvi demand, increased awareness, a new marketing campaign, an expanded sales team, and greater adoption across the authorized treatment center network.
Margin execution improved alongside revenue growth. Gross margin was 56%, excluding depreciation and amortization, reflecting higher Amtagvi sales volume, cost optimization, and maturing internal manufacturing efficiencies. R&D expenses decreased by approximately 6% compared with 1Q26, which management described as the fourth straight quarter of improvements. The reported combination of higher revenue, improving gross margin, and lower sequential R&D expense points to continued operating-efficiency progress.
Commercial infrastructure continues to expand. The ATC network exceeded 95 U.S., Canadian, and Australian centers, with community ATCs representing a third of the network. Iovance expects at least 110 ATCs to be active by the end of 2026. Internationally, the Australian marketing authorization application was approved, the U.K. application was resubmitted in early July under expedited review, and a Swiss decision is expected in 1H27. These regulatory and network developments are central to the next phase of Amtagvi access expansion.
Management is reviewing its FY26 total revenue guidance of $350 million to $370 million based on second-quarter sales and current demand trends, but did not issue a revised range in this release. It expects gross-margin improvements to continue, excluding occasional one-time items. The company reported a cash position of approximately $304 million as of June 30, 2026, consisting of cash, cash equivalents, short-term investments, and restricted cash, and stated that current cash is expected to fund operations into 2H28.
The clinical pipeline added regulatory and development milestones. FDA Fast Track Designation was granted for lifileucel in soft tissue sarcomas, while IOV-LUN-202 enrollment is nearly complete in pivotal cohorts and program updates are expected in 4Q26. The key near-term operating issues are the third-quarter revenue-guidance update, sustained gross-margin improvement, ATC activation, international regulatory progress, and forthcoming pipeline data and program updates.
Management, verbatim
Second-quarter revenue reached a record $99.3 million with gross margin of 56%, driven by continued U.S. Amtagvi demand,
Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer
Not in the filing
stated, not guessed- GAAP gross profit, operating income or loss, net income or loss, and diluted EPS were not provided in the supplied filing text.
- Non-GAAP operating income or loss, net income or loss, and EPS were not provided in the supplied filing text.
- Prior-year and prior-quarter gross margin were not provided.
- Amtagvi prior-year revenue and prior-quarter revenue were not provided. The release states Amtagvi revenue was up 40% from 4Q25, but does not provide the corresponding revenue amount.
- Operating cash flow and free cash flow were not provided.
- Debt was not provided.
- Share repurchases, dividends, and other capital-return amounts were not provided.
- FY26 operating-expense guidance and tax-rate guidance were not provided.
- A revised FY26 revenue-guidance range was not provided.
- A previous outlook section was not provided; therefore, no reported-versus-prior-guidance comparison is included.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.